US 10612025
Antisense oligonucleotides for the treatment of eye disease
granted A61KA61K31/7088A61K31/712
Quick answer
US patent 10612025 (Antisense oligonucleotides for the treatment of eye disease) held by ProQR Therapeutics II B.V. expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Tue Apr 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61K, A61K31/7088, A61K31/712, A61P, A61P27/02